Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A-Reference-Cited by-同舟云学术

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Published:2015-08-27 Issue:9 Volume:126 Page:1078-1085
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Konkle Barbara A.¹,Stasyshyn Oleksandra²,Chowdary Pratima³,Bevan David H.⁴,Mant Tim⁵,Shima Midori⁶,Engl Werner⁷,Dyck-Jones Jacqueline⁸,Fuerlinger Monika⁷,Patrone Lisa⁸,Ewenstein Bruce⁸,Abbuehl Brigitt⁷

Affiliation:

1. Puget Sound Blood Center and University of Washington, Seattle, WA;

2. Academy of Medical Sciences of Ukraine, Lviv, Ukraine;

3. Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, United Kingdom;

4. St. Thomas’ Hospital, London, United Kingdom;

5. Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom;

6. Nara Medical University Hospital, Nara, Japan;

7. Baxalta Innovations GmbH, Vienna, Austria; and

8. Baxalta US Inc., Westlake Village, CA

Abstract

Key Points BAX 855, a pegylated full-length rFVIII with extended half-life, was highly effective in the prevention and treatment of bleeding events. No subjects receiving BAX 855 developed FVIII inhibitory antibodies nor experienced unexpected adverse events.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/9/1078/1391494/1078.pdf

Reference23 articles.

1. Guidelines for the management of hemophilia.;Srivastava;Haemophilia,2013

2. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.;Björkman;Clin Pharmacokinet,2001

3. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.;Björkman;Eur J Clin Pharmacol,2009

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent;Current Pharmaceutical Design;2024-08

3. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A;Blood Advances;2024-05-30

4. Pegylation, a Successful Strategy to Address the Storage and Instability Problems of Blood Products: Review 2011-2021;Current Pharmaceutical Biotechnology;2024-02

5. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15